While TP53 is at present only used as a therapy stratifier in MCL and CLL, there are multiple studies that have shown that pathogenic TP53 aberrations are associated with inferior therapeutic efficacy and survival outcomes in other mature B-cell lymphomas as well, most notably in (D)LBCL[3, 11]. This evidence concerns the gene TP53 and B-cell non-Hodgkin lymphoma.